Literature DB >> 29436415

Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls.

Romney M Humphries1, Mary Jane Ferraro2, Janet A Hindler3.   

Abstract

Antimicrobial resistance is the most pressing medical challenge of the past decade. At the front line are clinical laboratories, which are responsible for accurately reporting antimicrobial susceptibility test (AST) results to clinicians and public health authorities. The ability of the laboratory to detect resistance has been hampered by several factors. In 2016, the 21st Century Cures Act was signed into law, marking an important step toward resolving many regulatory dilemmas that hampered development and updates to commercial AST systems (cASTs). We describe the pathway and history of U.S. regulation of cASTs and outline both the rewards and unmet needs possible from the 21st Century Cures Act.
Copyright © 2018 American Society for Microbiology.

Keywords:  21st Century Cures Act; Clinical and Laboratory Standards Institute; Food and Drug Administration; antimicrobial susceptibility testing; breakpoints

Mesh:

Substances:

Year:  2018        PMID: 29436415      PMCID: PMC5925699          DOI: 10.1128/JCM.00139-18

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Rationale for the 2010 Revised Susceptibility Breakpoints for Cephalosporins, Aztreonam, and Carbapenems for Enterobacteriaceae.

Authors:  Michael N Dudley
Journal:  J Pediatric Infect Dis Soc       Date:  2012-06       Impact factor: 3.164

Review 2.  Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance.

Authors:  Melvin P Weinstein; Keith P Klugman; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

3.  The Point of Antimicrobial Susceptibility Testing Is to Inform Antimicrobial Prescribing.

Authors:  Kayla R Stover; Christopher M Bland; Jason C Gallagher
Journal:  Clin Infect Dis       Date:  2016-10-06       Impact factor: 9.079

4.  Detection of Klebsiella pneumoniae carbapenemase (KPC) production in non-Klebsiella pneumoniae Enterobacteriaceae isolates by use of the Phoenix, Vitek 2, and disk diffusion methods.

Authors:  Christopher D Doern; W Michael Dunne; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

5.  Emerging Resistance, New Antimicrobial Agents  …  but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory Landscape.

Authors:  R M Humphries; J A Hindler
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

6.  Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.

Authors:  Sarah M Bartsch; Susan S Huang; Kim F Wong; Rachel B Slayton; James A McKinnell; Daniel F Sahm; Krystyna Kazmierczak; Leslie E Mueller; John A Jernigan; Bruce Y Lee
Journal:  J Clin Microbiol       Date:  2016-08-31       Impact factor: 5.948

Review 7.  The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Authors:  Fred C Tenover; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2007-03-28       Impact factor: 9.079

8.  Carbapenem-Resistant Enterobacteriaceae Detection Practices in California: What Are We Missing?

Authors:  Romney M Humphries; Janet A Hindler; Erin Epson; Sam Horwich-Scholefield; Loren G Miller; Job Mendez; Jeremias B Martinez; Jacob Sinkowitz; Darren Sinkowtiz; Christina Hershey; Patricia Marquez; Sandeep Bhaurla; Marcelo Moran; Lindsey Pandes; Dawn Terashita; James A McKinnell
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

Review 9.  Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Authors:  Michael N Dudley; Paul G Ambrose; Sujata M Bhavnani; William A Craig; Mary Jane Ferraro; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2013-01-18       Impact factor: 9.079

Review 10.  The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds.

Authors:  Ana Espinel-Ingroff; John Turnidge
Journal:  Rev Iberoam Micol       Date:  2016-06-11       Impact factor: 1.044

  10 in total
  9 in total

1.  Evaluation of the MicroScan Colistin Well and Gradient Diffusion Strips for Colistin Susceptibility Testing in Enterobacteriaceae.

Authors:  Joseph D Lutgring; Anny Kim; Davina Campbell; Maria Karlsson; Allison C Brown; Eileen M Burd
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

Review 2.  Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.

Authors:  Romney M Humphries; April N Abbott; Janet A Hindler
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

Review 3.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

4.  Bringing Antimicrobial Susceptibility Testing for New Drugs into the Clinical Laboratory: Removing Obstacles in Our Fight against Multidrug-Resistant Pathogens.

Authors:  James E Kirby; Thea Brennan-Krohn; Kenneth P Smith
Journal:  J Clin Microbiol       Date:  2019-11-22       Impact factor: 5.948

5.  Stop Waiting for Tomorrow: Disk Diffusion Performed on Early Growth Is an Accurate Method for Antimicrobial Susceptibility Testing with Reduced Turnaround Time.

Authors:  Daniel M Webber; Meghan A Wallace; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2022-02-02       Impact factor: 11.677

6.  Editorial: Beyond Antimicrobials: Non-traditional Approaches to Combating Multidrug-Resistant Bacteria.

Authors:  Natalia V Kirienko; Laurence Rahme; You-Hee Cho
Journal:  Front Cell Infect Microbiol       Date:  2019-10-11       Impact factor: 5.293

7.  Raising the Bar: Improving Antimicrobial Resistance Detection by Clinical Laboratories by Ensuring Use of Current Breakpoints.

Authors:  Patricia J Simner; Carol A Rauch; Isabella W Martin; Kaede V Sullivan; Daniel Rhoads; Robin Rolf; Rosemary She; Rhona J Souers; Christina Wojewoda; Romney M Humphries
Journal:  Open Forum Infect Dis       Date:  2022-02-07       Impact factor: 3.835

8.  Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study.

Authors:  Jeffrey R Strich; Sarah Warner; Yi Ling Lai; Cumhur Y Demirkale; John H Powers; Robert L Danner; Sameer S Kadri
Journal:  Lancet Infect Dis       Date:  2020-06-04       Impact factor: 71.421

Review 9.  New strategies and structural considerations in development of therapeutics for carbapenem-resistant Enterobacteriaceae.

Authors:  Thea Brennan-Krohn; Roman Manetsch; George A O'Doherty; James E Kirby
Journal:  Transl Res       Date:  2020-03-02       Impact factor: 7.012

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.